Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FBL-MTX in Rheumatoid Arthritis
NCT06565273Phase 2Completed
- Sponsor
- Solfarcos
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of FBL-MTX in rheumatoid arthritis (RA), sponsored by Solfarcos. Started Jul 2024; status: completed.
02
Drugs
FBL-MTX
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06565273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565273.